Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs Tirzepatide in Type 2 Diabetes
NCT06221969Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06221969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221969.